Two randomized phase 3 trials of safety and efficacy of bremelanotide 1.75 mg have found that the drug significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.
Hypo Sexual Desire Disorder Resource Center
The statement was prompted because of the uncertain benefits and risks of treating women with testosterone.
A recent study of women complaining of low or absent sexual desire found their low desire may be linked to hypothalamic-pituitary-adrenal (HPA) axis dysregulation.
A recent study on patients with epilepsy compared the frequency of sexual problems in this population with the general population.
A recent study examined how bicycle seats may play a role in the prevalence of sexual dysfunction among female adult bicyclists.
This month's quiz reviews some of the major takeaways from the July 2019 article, "Genitourinary syndrome of menopause: Underdiagnosed and undertreated."
New research examines the negative effects of chronic pelvic pain on aspects of sex such as lubrication.
Ob/gyns treating patients with epilepsy should be aware of their higher risk for sexual dysfunction while also recognizing that the cause may be multifactorial.
Although PFMT has been primarily evaluated for urinary incontinence, new research suggests it may also have benefits for women who report painful sex.
Despite the prevalence of GSM, the condition continues to be under-recognized and undertreated due to a combination of patient and provider factors. Providers need to take the initiative in screening and patient education.